Biomarkers in early diagnosis of prostate cancer

Abstract

Fast development of laboratory diagnostic methods has allowed introducing various biomarkers for detection of prostate cancer to clinical practice. However, difficulties in visualization of tumor foci remain one of the most urgent problems. As a result, prostatic biopsy is often performed only on a basis of elevated levels of prostate-specific antigen and data of rectal examination. These tests do not always allow to differentiate suspicious areas, and the material is taken from standard zones. An existing alternative is MRI-guided biopsy, but the related time and financial costs impose significant limitations on extensive use of this technique. Implementation of new biomarkers will create an individualized approach to diagnostics, treatment and prognosis of prostate cancer for each patient.